Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that works to relieve pain and reduce inflammation. Voltaren Gel 12 Hour is a non-greasy, easy to use alternative to the familiar. Voltaren Gel 12 Hour relieves pain and reduces inflammation in the body. It is clinically proven to help pain and reduce inflammation in your body.
Voltaren Gel 12 Hour is used to treat pain in: stomach, back, muscle and joints
Take 1 tube of Voltaren Gel 12 Hour by mouth as needed, usually one to 4 times a day. The amount of medicine in the tube, give or take, depends on the length of the treatment. If the tube is open, the amount of medicine in the tube can vary from tube to tube. Take the lowest dose for the shortest time. Do not take more or longer than 2 weeks, unless a doctor has told you to. Use for longer than that. The medicine will not work same for everyone. If you get any side effects, or feel the symptom changes, talk to your doctor. See also Warning section.
Take 2% diclofenac gel 12 hours in the morning and 1% afternoempresaries at the same time every day. Do not take more than 2 weeks, except by the doctor.
Do not use Voltaren Gel 12 Hour if:
If you are taking prescription medicine, ask your doctor about alternative ways to use this medicine. Ask your pharmacist how to use it safely.
Do not use Voltaren Gel 12 Hour if you are pregnant or breastfeeding without consulting a doctor. Do not use if you:
Consult your doctor before use if you are pregnant, breast feeding, using any other medication, or if you have any other medical conditions.
Do not take the lowest dose for the shortest time.
Do you have pain, tenderness or swelling associated with inflammation or injury? Rub Voltaren Emulgel on your point of pain for targeted pain relief. Voltaren Emulgel penetrates deep into your skin with a dual benefit that relieves pain and reduces inflammation. Voltaren Emulgel is a medicated product containing a non-steroidal anti-inflammatory drug, or NSAID, in the form of an emulsion gel. The active ingredient (diclofenac) in our gels penetrates deep into the skin and treats thecause of pain. It works differently from heat or cooling rubs, which contain ingredients that stimulate nerves in the skin to provide a sensation of heating or cooling. Voltaren Emulgel instead allows an anti-inflammatory (diclofenac) to penetrate the skin deep down in order to relieve pain and reduce inflammation where you need it. Voltaren Emulgel can be used for the relief of body pain, inflammation and swelling in Soft-tissue injuries, trauma of the tendons, ligaments, muscles and joints, due to sprains, strains, bruises and backache (e.g. in sports injuries), Localised forms of soft tissue rheumatism including tendonitis and bursitis. Voltaren Emulgel formula combines the qualities of a gel and a cream, that has an appealing smell, is easy to rub in and rapidly absorbed, and even provides a cooling and soothing effect when applied to the skin. Delivering pain relief to help you get back to the movement that you love! Carefully read all information provided with the product before use.
50g
Rub gently into the affected area 3 or 4 times daily. Do not use for more than 2 weeks except on medical advice.
Do not use Voltaren Emulgel: On children under 12 yearsIf you are pregnant or breastfeedingIf you are allergic to diclofenac, aspirin, any other anti-inflammatory medicines or pain relieversIf tube seal is broken or missingUntil you read the enclosed leaflet carefullyStop use and see your doctor immediately if: You experience an allergic reaction. While using this product: Unless a doctor or pharmacist has told you to, do not use this product with other medicines that you are taking regularly. For external use onlyAvoid contact with eyes.
Diclofenac diethylamine 11.6 mg/g
Contains isopropyl alcohol as a preservative. Contains benzoates.
Vegan Emulgel EmulgelVegan Emulgel with Diclofenac Diethylamine 11.6 mg/gAvoid contact with eyes.
Always read the label and follow the directions for use.
Gelen Pharma GelSoft-tissue injuries and tendonitis of the tendons, ligaments, and muscles. NSAIDs, including Voltaren Emulgel, can cause a variety of side effects, some of which are more common than others. This is due to the drug's effects on nerve signals that trigger inflammation and pain. Although Voltaren Emulgel has proven to be very effective in treating pain, inflammation and swelling, it also causes more water weight than non-emulgel pain relievers. To make the most of Voltaren Emulgel, keep the gel in the blister pack or blister package and apply the gel a few times a day, until it is absorbed into the skin. The amount of gel that is applied can vary from 1 to 3 gm/day, and it is important to read the label and follow the directions for use. If you are using this product for the local area: Rub gently into the affected area 3 or 4 times daily, until all the water has been absorbed. Do not use for more than 3 days unless directed by a doctor.
Voltaren Ophthalmic is a topical solution formulated for use in the eye where inflammation is present, but is also used in other areas where inflammation is present. It contains diclofenac diethylamine, an ingredient that is known to contribute to an excessive inflammation in the eye, such as in the treatment of corneal ulcers. Voltaren Ophthalmic is a gel, which is applied directly to the eyes. It works by blocking the production of the pro-inflammatory substances in the eye, such as diclofenac, which are produced by the damaged cornea. Voltaren Ophthalmic works by relieving the symptoms of corneal ulcers. Voltaren Ophthalmic is used to treat various eye conditions, including corneal ulcers and corneal infections. It is also used to reduce swelling in the eye, which can be caused by the action of certain hormones in the body. Voltaren Ophthalmic is a topical drug. It is applied directly to the eyes. Voltaren Ophthalmic is available in the form of a gel or a troche.
Product Info:Voltaren Ophthalmic is a topical drug that contains diclofenac diethylamine, an ingredient that is known to contribute to an excessive inflammation in the eye, such as in the treatment of corneal ulcers. It works by relieving the symptoms of corneal ulcers.
It is available in the form of a gel or a troche.
Voltaren Emulgel Extra Strengthis clinically proven to help reduce inflammation and pain in the primary dysmenstrual syndrome (PMDD) condition. Its active ingredient diclofenac diethylamine is an emulgel, which creates a jelly-like texture and firmness when rubbed into the body. This gel is used to relieve pain and inflammation in the primary dysmenstrual syndrome (PDS) condition when a large number of men are unable to achieve an adequate and regular menstrual cycle.
is a gel that is applied directly to the affected area. The Emulgel Extra Strength formula is very similar to the Emulgel Gel formula applied to the skin, with the difference that the Emulgel Extra Strength gel penetrates deep into the skin directly to produce an effective gel. This formula delivers a rapid cooling gel to the affected area, where it penetrates deeply into the skin to produce effective and lasting relief from pain, inflammation, and discomfort.
For external use only
The ingredients in Voltaren Emulgel Extra Strength are: Diclofenac Diethylamine Gelatine (Eudrag) 30 g
The ingredients in Voltaren Emulgel Extra Strength are: Diclofenac Diethylamine Gelatine (Eudrolim) 5.2 g
Each gram of gel contains: Diclofenac diethylamine 1.25 g
Read MoreoveraskVoltaren Emulgel Extra Strength contains a combination of ingredients that help relieve menstrual pain, including diclofenac, and provide a fast and pain-free way to provide relief from pain in primary dysmenstrual syndrome (PMDD) conditions.
Each gram of gel contains: Diclofenac Diethylamine Gelatine (Eudrag) 5.2 g
ApplyDirectionsFor external use onlyRead MoreFree AdviceThe Complainant is F. Hoffmann-La Roche AG of Basel, Switzerland, and Respondent is E. Enterprises of India of India, India.
The disputed domain names,Voltaren,VoltarenRxVoltarenPharmaVoltarenSciencesVoltarenPharmaPlus, andare registered under the laws of the State of Switzerland. The disputed domain names are not registered with the Swiss authorities.
The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on October 14, 2016. On October 15, 2016, the Center transmitted by email to the Registrar a request for registrar verification in connection with the disputed domain names. The Registrar transmitted on October 17, 2016, a request for registrar verification in connection with the disputed domain names in accordance with the Complaint, to the Center. On the same date, the Registrar transmitted by email to the Center its verification response confirming that the Respondent is listed as the registrant and providing the contact details. The Center verified that the Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”).
In accordance with the Rules, paragraphs 2(a) and 4(a), the Center formally notified the Respondent of the Complaint, and the proceedings commenced on October 16, 2016. In accordance with the Rules, paragraph 5(a), the due date for Response was October 17, 2016. The Respondent did not submit any response. Accordingly, the Center notified the Respondent’s default on October 18, 2016.
The Center appointed David A. Koppel as the sole panelist in this matter on October 20, 2016. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7.
The Complainant is a pharmaceutical company with offices in Switzerland and India. The Complainant and its subsidiaries have operated a wide range of businesses throughout the world including pharmaceutical, biotechnology, cosmetic and medical products. The Complainant has an estimated annual sales of approximately USD 1 billion in the United States, and a total turnover of approximately USD 100 million.
The Complainant, which has rights in the disputed domain names, is the owner of the Complainant’s Internet-to-Internet connection and has a number of business units. The Complainant operates in over 200 countries and has more than 500,000 domain names registered on the Internet. The Complainant is the owner of one of the disputed domain names.
The Respondent, who is the owner of the disputed domain names, was formerly the sole owner of the domain names and the Respondent is the sole director of the Respondent’s business. The Respondent was originally the executive director of the Complainant and was then the sole director of the Complainant’s Internet-to-Internet connection. The Respondent was originally the executive director of the Complainant and then the executive director of the Respondent’s Internet-to-Internet connection. The Respondent’s office is located in Switzerland.
The Complainant is a Swiss corporation registered in Switzerland and has a number of registered domain names on the Internet. The Complainant’s Internet-to-Internet connection and the Respondent’s Office are located in Switzerland. The Complainant’s Internet-to-Internet connection and the Respondent’s Office are located in India.
Stade de France Pharmacy